Document Type
Article
Publication Title
Oncotarget
Abstract
mTOR activation suppresses autophagy by phosphorylating ULK1 at S757 and suppressing its enzymatic activity. Here we report that feedback activation of mTOR in the PI-3 kinase pathway by two p70 S6 kinase (S6K1) inhibitors (PF-4708671 and A77 1726, the active metabolite of an immunosuppressive drug leflunomide) or by S6K1 knockdown did not suppress but rather induced autophagy. Suppression of S6K1 activity led to the phosphorylation and activation of AMPK, which then phosphorylated ULK1 at S555. While mTOR feedback activation led to increased phosphorylation of ULK1 at S757, this modification did not the disrupt ULK1-AMPK interaction nor dampen ULK1 S555 phosphorylation and the induction of autophagy. In addition, inhibition of S6K1 activity led to JNK activation, which also contributed to autophagy. 5Z-7-oxozeaenol, a specific inhibitor of TAK1, or TAK1 siRNA blocked A77 1726-induced activation of AMPK and JNK, and LC3 lipidation. Taken together, our study establishes S6K1 as a key player in the PI-3 kinase pathway to suppress autophagy through inhibiting AMPK and JNK in a TAK1-dependent manner.
DOI
10.18632/oncotarget.16737
Publication Date
5-2-2017
Keywords
autophagy, leflunomide, mTOR, p70 S6 kinase ULK
ISSN
1949-2553
Recommended Citation
Xu X, Sun J, Song R, Doscas ME, Williamson AJ, Zhou J, Sun J, Jiao X, Liu X, Li Y. Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726, the Active Metabolite of Leflunomide, Induces Autophagy Through TAK1-Mediated AMPK and JNK Activation. Oncotarget. 2017; 8(18). doi: 10.18632/oncotarget.16737.
